Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Impax Laboratories Receives Tentative FDA Approval For Generic Cymbalta® Delayed-Release 20, 30 And 60 Mg Capsules

Impax Laboratories Receives Tentative FDA Approval For Generic Cymbalta® Delayed-Release 20, 30 And 60 Mg Capsules

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirmed that the U.

Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy And Safety In APEX-PD Phase III Study In Treatment Of Early Parkinson’s Disease

Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy And Safety In APEX-PD Phase III Study In Treatment Of Early Parkinson’s Disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc.

Impax Laboratories Receives Final FDA Approval For Generic Allegra-D 60mg/120mg Tablets

Impax Laboratories Receives Final FDA Approval For Generic Allegra-D 60mg/120mg Tablets

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.

Impax Laboratories To Present At The Credit Suisse 19th Annual Healthcare Conference

Impax Laboratories To Present At The Credit Suisse 19th Annual Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Credit Suisse 19 th Annual Healthcare Conference on Friday, November 12, at 9:00 a.

Impax Laboratories Management Discusses Q3 2010 Results – Earnings Call Transcript

Impax Laboratories Management Discusses Q3 2010 Results â¿¿ Earnings Call Transcript

Impax Laboratories Reports Growth In Revenue, Profit And Earnings In The Third Quarter 2010

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company’s Strategic...

Impax Laboratories Announces Litigation Against Shire Relating To Supply Of Generic Adderall XR®

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has initiated litigation against Shire LLC and Shire Laboratories, Inc.

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2010 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2010 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its third quarter 2010 financial results will be released before the market opens on Tuesday, November 2, 2010 and will be available on Impax’s Web ...

Impax Laboratories To Present At The Jefferies 2010 Global SpecPharma And European Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference on Tuesday, October 5, at 2:30 p.

Impax Laboratories To Present At The UBS Global Life Sciences Conference

Impax Laboratories, Inc. (NASDAQ:IPXL) today announced that the Company will present at the UBS Global Life Sciences Conference on Monday, September 20, at 10:30 a.

Impax Laboratories To Present At The Morgan Stanley Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Morgan Stanley Global Healthcare Conference on Monday, September 13, at 9:45 a.

Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson’s Disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc.

CME Director Buys $1.2M Worth

Director William Shepard buys 5,000 shares worth $1.2 million.

Impax Laboratories Confirms Patent Challenge Relating To VYTORIN®, 10 Mg/80 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by MSP Singapore Co.

Impax Laboratories Enters Into Development Agreement With Perrigo

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company with respect to the development and commercialization of two extended topical drug products.

Impax Laboratories Inc. Q2 2010 Earnings Call Transcript

Impax Laboratories Inc. Q2 2010 Earnings Call Transcript

Impax Laboratories Continues Strong Growth In Revenue, Profit And Earnings In The Second Quarter 2010

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported strong growth in the second quarter of 2010 due to an increase in sales from its Global Product sales channel.

Market Movers, Action Alerts Plus, Great Growth Stocks

Guests include Ken Shreve, TheStreet's Market Movers portfolio manager, Stephanie Link, director of research for Jim Cramer's Action Alerts Plus and Bob Auer, portfolio manager for the Auer Growth fund.

Impax Laboratories Receives Final FDA Approval For Generic OPANA® ER Tablets

Impax Laboratories Receives Final FDA Approval For Generic OPANA® ER Tablets

Impax Laboratories, Inc. (NASDAQ:IPXL) today announced that the U.

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2010 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2010 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its second quarter 2010 financial results will be released before the market opens on Tuesday, August 3, 2010 and will be available on Impax’s Web ...

Impax Laboratories Confirms Patent Challenge Relating To RENVELA®, 2.4 G And 0.8 G (For Suspension)

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation (“Genzyme”) in connection with RENVELA® (sevelamer carbonate for ...

10 Stocks to Buy for Earnings Season

Earnings season is the best opportunity to identify the best investments in the stock market for your retirement money.

Impax Laboratories To Present At The Wells Fargo Securities Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Wells Fargo Securities Healthcare Conference on Wednesday, June 23rd, at 4:00 p.

Tape Feels Like a Repeat of 2004

Because of this, we could see an opportunity to build long-term positions sometime in the fourth quarter.

Impax Laboratories To Present At The Goldman Sachs 31st Annual Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs Healthcare Conference on Tuesday, June 15th, at 2:30 p.

Impax Laboratories And Endo Pharmaceuticals Settle Pending Litigation For Opana® ER And Announce Development And Co-Promotion Agreement

Impax Laboratories, Inc. (Nasdaq: IPXL) today announced that it has reached agreement with Endo Pharmaceuticals (Nasdaq: ENDP) and Penwest Pharmaceuticals (Nasdaq PPCO) to settle pending U.

Impax Laboratories To Present At Upcoming Investor Conferences On June 10

Impax Laboratories, Inc. (Nasdaq: IPXL) today announced that the Company will present at the Jefferies 2010 Global Life Sciences Conference on Thursday, June 10 th, at 9:30 a.

Impax Laboratories Enters Into Development And Supply Agreement With IGI Laboratories

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has entered into a product development and supply agreement with IGI Laboratories, Inc.

Impax Laboratories Announces Voting Results From 2010 Annual Meeting Of Stockholders

Impax Laboratories, Inc. (NASDAQ: IPXL) held its 2010 Annual Meeting of Stockholders today in San Mateo, California.

Qualcomm: Analysts' Upgrades, Downgrades

Qualcomm was initiated with a Neutral rating, Sterne Agee said.